[
    "METHODS\u00a0OF\u00a0CANCER\u00a0TREATMENT\u00a0WITH\u00a0ANTI-OX40\u00a0ANTIBODY\u00a0IN\u00a0COMBINATION\u00a0WITH\u00a0CHEMOTHERAPEUTIC\u00a0AGENTSFIELD\u00a0OF\u00a0THE\u00a0DISCLOSURE</p>Disclosed\u00a0herein\u00a0are\u00a0methods\u00a0of\u00a0treating\u00a0cancer\u00a0with\u00a0antibodies\u00a0or\u00a0antigen-binding\u00a0fragments\u00a0thereof\u00a0that\u00a0bind\u00a0to\u00a0human\u00a0OX40\u00a0in\u00a0combination\u00a0with\u00a0chemotherapy\u00a0agents.</p>BACKGROUND\u00a0OF\u00a0THE\u00a0DISCLOSURE</p>OX40\u00a0(also\u00a0known\u00a0as\u00a0ACT35,\u00a0CD134,\u00a0or\u00a0TNFRSF4)\u00a0is\u00a0an\u00a0approximately\u00a050\u00a0KD\u00a0type\u00a0I\u00a0transmembrane\u00a0glycoprotein,\u00a0and\u00a0a\u00a0member\u00a0of\u00a0the\u00a0tumor\u00a0necrosis\u00a0factor\u00a0receptor\u00a0super\u00a0family\u00a0(TNFRSF)\u00a0(Croft,\u00a02010;\u00a0Gough\u00a0and\u00a0Weinberg,\u00a02009)\u00a0.\u00a0Mature\u00a0human\u00a0OX40\u00a0is\u00a0composed\u00a0of\u00a0249\u00a0amino\u00a0acid\u00a0(AA)\u00a0residues,\u00a0with\u00a0a\u00a037\u00a0AA\u00a0cytoplasmic\u00a0tail\u00a0and\u00a0a\u00a0185\u00a0AA\u00a0extracellular\u00a0region.\u00a0The\u00a0extracellular\u00a0domain\u00a0of\u00a0OX40\u00a0contains\u00a0three\u00a0complete\u00a0and\u00a0one\u00a0incomplete\u00a0cysteine-rich\u00a0domains\u00a0(CRDs)\u00a0.\u00a0The\u00a0intracellular\u00a0domain\u00a0of\u00a0OX40\u00a0contains\u00a0one\u00a0conserved\u00a0signaling-related\u00a0QEE\u00a0motif,\u00a0which\u00a0mediates\u00a0binding\u00a0to\u00a0several\u00a0TNFR-associated\u00a0factors\u00a0(TRAF)\u00a0including\u00a0TRAF2,\u00a0TRAF3,\u00a0and\u00a0TRAF5,\u00a0allowing\u00a0OX40\u00a0to\u00a0link\u00a0to\u00a0intracellular\u00a0kinases\u00a0(Arch\u00a0and\u00a0Thompson,\u00a01998;\u00a0Willoughby\u00a0et\u00a0al.,\u00a02017)\u00a0.</p>OX40\u00a0was\u00a0initially\u00a0discovered\u00a0on\u00a0activated\u00a0rat\u00a0CD4\n      <sup>+</sup>\u00a0T\u00a0cells,\u00a0and\u00a0murine\u00a0and\u00a0human\u00a0homologs\u00a0were\u00a0subsequently\u00a0cloned\u00a0from\u00a0T\u00a0cells\u00a0(al-Shamkhani\u00a0et\u00a0al.,\u00a01996;\u00a0Calderhead\u00a0et\u00a0al.,\u00a01993)\u00a0.\u00a0In\u00a0addition\u00a0to\u00a0expression\u00a0on\u00a0activated\u00a0CD4\n      <sup>+</sup>\u00a0T\u00a0cells,\u00a0including\u00a0T\u00a0helper\u00a0(Th)\u00a01\u00a0cells,\u00a0Th2\u00a0cells,\u00a0Th17\u00a0cells,\u00a0as\u00a0well\u00a0as\u00a0regulatory\u00a0T\u00a0(Treg)\u00a0cells,\u00a0OX40\u00a0expression\u00a0has\u00a0also\u00a0been\u00a0found\u00a0on\u00a0the\u00a0surface\u00a0of\u00a0activated\u00a0CD8\n      <sup>+</sup>\u00a0T\u00a0cells,\u00a0natural\u00a0killer\u00a0(NK)\u00a0T\u00a0cells,\u00a0neutrophils,\u00a0and\u00a0NK\u00a0cells\u00a0(Croft,\u00a02010)\u00a0.\u00a0In\u00a0contrast,\u00a0low\u00a0OX40\u00a0expression\u00a0is\u00a0found\u00a0on\u00a0\n      CD4\n      <sup>+</sup>\u00a0and\u00a0CD8\n      <sup>+</sup>\u00a0T\u00a0cells,\u00a0as\u00a0well\u00a0as\u00a0on\u00a0most\u00a0resting\u00a0memory\u00a0T\u00a0cells\u00a0(Croft,\u00a02010;\u00a0Soroosh\u00a0et\u00a0al.,\u00a02007)\u00a0.\u00a0The\u00a0surface\u00a0expression\u00a0of\u00a0OX40\u00a0on\u00a0\n      T\u00a0cells\u00a0is\u00a0transient.\u00a0After\u00a0TCR\u00a0activation,\u00a0OX40\u00a0expressio",
    "te\u00a0ligand\u00a0binding\u00a0to\u00a0the\u00a0receptor.</p>The\u00a0term\u00a0\"corresponding\u00a0human\u00a0germline\u00a0sequence\"\u00a0refers\u00a0to\u00a0the\u00a0nucleic\u00a0acid\u00a0sequence\u00a0encoding\u00a0a\u00a0human\u00a0variable\u00a0region\u00a0amino\u00a0acid\u00a0sequence\u00a0or\u00a0subsequence\u00a0that\u00a0shares\u00a0the\u00a0highest\u00a0determined\u00a0amino\u00a0acid\u00a0sequence\u00a0identity\u00a0with\u00a0a\u00a0reference\u00a0variable\u00a0region\u00a0amino\u00a0acid\u00a0sequence\u00a0or\u00a0subsequence\u00a0in\u00a0comparison\u00a0to\u00a0all\u00a0other\u00a0known\u00a0variable\u00a0region\u00a0amino\u00a0acid\u00a0sequences\u00a0encoded\u00a0by\u00a0human\u00a0germline\u00a0immunoglobulin\u00a0variable\u00a0region\u00a0sequences.\u00a0The\u00a0corresponding\u00a0human\u00a0germline\u00a0sequence\u00a0can\u00a0also\u00a0refer\u00a0to\u00a0the\u00a0human\u00a0variable\u00a0region\u00a0amino\u00a0acid\u00a0sequence\u00a0or\u00a0subsequence\u00a0with\u00a0the\u00a0highest\u00a0amino\u00a0acid\u00a0sequence\u00a0identity\u00a0with\u00a0a\u00a0reference\u00a0variable\u00a0region\u00a0amino\u00a0acid\u00a0sequence\u00a0or\u00a0subsequence\u00a0in\u00a0comparison\u00a0to\u00a0all\u00a0other\u00a0evaluated\u00a0variable\u00a0region\u00a0amino\u00a0acid\u00a0sequences.\u00a0The\u00a0corresponding\u00a0human\u00a0germline\u00a0sequence\u00a0can\u00a0be\u00a0framework\u00a0regions\u00a0only,\u00a0complementarity\u00a0determining\u00a0regions\u00a0only,\u00a0framework\u00a0and\u00a0complementary\u00a0determining\u00a0regions,\u00a0a\u00a0variable\u00a0segment\u00a0(as\u00a0defined\u00a0above)\u00a0,\u00a0or\u00a0other\u00a0combinations\u00a0of\u00a0sequences\u00a0or\u00a0subsequences\u00a0that\u00a0comprise\u00a0a\u00a0variable\u00a0region.\u00a0Sequence\u00a0identity\u00a0can\u00a0be\u00a0determined\u00a0using\u00a0the\u00a0methods\u00a0described\u00a0herein,\u00a0for\u00a0example,\u00a0aligning\u00a0two\u00a0sequences\u00a0using\u00a0BLAST,\u00a0ALIGN,\u00a0or\u00a0another\u00a0alignment\u00a0algorithm\u00a0known\u00a0in\u00a0the\u00a0art.\u00a0The\u00a0corresponding\u00a0human\u00a0germline\u00a0nucleic\u00a0acid\u00a0or\u00a0amino\u00a0acid\u00a0sequence\u00a0can\u00a0have\u00a0at\u00a0least\u00a0about\u00a090%,\u00a091,\u00a092%,\u00a093%,\u00a094%,\u00a095%,\u00a096%,\u00a097%,\u00a098%,\u00a099%,\u00a0or\u00a0100%sequence\u00a0identity\u00a0with\u00a0the\u00a0reference\u00a0variable\u00a0region\u00a0nucleic\u00a0acid\u00a0or\u00a0amino\u00a0acid\u00a0sequence.</p>The\u00a0term\u00a0\"equilibrium\u00a0dissociation\u00a0constant\u00a0(K\n      <sub>D</sub>,\u00a0M)\u00a0\"\u00a0refers\u00a0to\u00a0the\u00a0dissociation\u00a0rate\u00a0constant\u00a0(kd,\u00a0time\n      <sup>-1</sup>)\u00a0divided\u00a0by\u00a0the\u00a0association\u00a0rate\u00a0constant\u00a0(ka,\u00a0time\n      <sup>-1</sup>,\u00a0M\n      <sup>-l</sup>)\u00a0.\u00a0Equilibrium\u00a0dissociation\u00a0constants\u00a0can\u00a0be\u00a0measured\u00a0using\u00a0any\u00a0known\u00a0method\u00a0in\u00a0the\u00a0art.\u00a0The\u00a0antibodies\u00a0of\u00a0the\u00a0present\u00a0disclosure\u00a0generally\u00a0will\u00a0have\u00a0an\u00a0equilibrium\u00a0dissociation\u00a0constant\u00a0of\u00a0less\u00a0than\u00a0 about\u00a010 \n      <sup>-7</sup>\u00a0or\u00a010\n      <sup>-8</sup>\u00a0M,\u00a0for\u00a0example,\u00a0less\u00a0than\u00a0about\u00a010\n      <sup>-9</sup>\u00a0M\u00a0or\u00a010\n      <sup>-10</sup>\u00a0M,\u00a0in\u00a0some\u00a0aspects,\u00a0less\u00a0than\u00a0about\u00a010\n      <sup>-11</sup>\u00a0M,\u00a010\n      <sup>-12</sup>\u00a0M\u00a0or\u00a010\n      <sup>-13</sup>\u00a0M.\n    </p>The\u00a0terms\u00a0\u201ccancer\u201d\u00a0or\u00a0\u201ctumor\u201d\u00a0herein\u00a0has\u00a0the\u00a0broadest\u00a0meaning\u00a0as\u00a0understood\u00a0in\u00a0the\u00a0art\u00a0and\u00a0refers\u00a0to\u00a0the\u00a0physiological\u00a0condition\u00a0in\u00a0mammals\u00a0that\u00a0is\u00a0typically\u00a0characterized\u00a0by\u00a0unregulated\u00a0cell\u00a0growth.\u00a0In\u00a0the\u00a0context\u00a0of\u00a0the\u00a0present\u00a0disclosure,\u00a0the\u00a0cancer\u00a0is\u00a0not\u00a0limited\u00a0to\u00a0certain\u00a0type\u00a0or\u00a0location.</p>The\u00a0term\u00a0\"combination\u00a0therapy\"\u00a0refers\u00a0to\u00a0the\u00a0administration\u00a0of\u00a0two\u00a0or\u00a0more\u00a0therapeutic\u00a0agents\u00a0to\u00a0treat\u00a0a\u00a0therapeutic\u00a0condition\u00a0or\u00a0disorder\u00a0described\u00a0in\u00a0the\u00a0present\u00a0disclosure.\u00a0Such\u00a0administration\u00a0encompasses\u00a0co-administration\u00a0of\u00a0these\u00a0therapeutic\u00a0agents\u00a0in\u00a0a\u00a0substantially\u00a0simultaneous\u00a0manner.\u00a0Such\u00a0administration\u00a0also\u00a0encompasses\u00a0co-administration\u00a0in\u00a0multiple,\u00a0or\u00a0in\u00a0separate\u00a0containers\u00a0(e.g.,\u00a0capsules,\u00a0powders,\u00a0and\u00a0liquids)\u00a0for\u00a0each\u00a0active\u00a0ingredient.\u00a0Powders\u00a0and/or\u00a0liquids\u00a0can\u00a0be\u00a0reconstituted\u00a0or\u00a0diluted\u00a0to\u00a0a\u00a0desired\u00a0dose\u00a0prior\u00a0to\u00a0administration.\u00a0In\u00a0addition,\u00a0such\u00a0administration\u00a0also\u00a0encompasses\u00a0use\u00a0of\u00a0each\u00a0type\u00a0of\u00a0therapeutic\u00a0agent\u00a0in\u00a0a\u00a0sequential\u00a0manner,\u00a0either\u00a0at\u00a0approximately\u00a0the\u00a0same\u00a0time\u00a0or\u00a0at\u00a0different\u00a0times.\u00a0In\u00a0either\u00a0case,\u00a0the\u00a0treatment\u00a0regimen\u00a0will\u00a0provide\u00a0beneficial\u00a0effects\u00a0of\u00a0the\u00a0drug\u00a0combination\u00a0in\u00a0treating\u00a0the\u00a0conditions\u00a0or\u00a0disorders\u00a0described\u00a0herein.\u00a0As\u00a0used\u00a0herein,\u00a0the",
    "ctronic\u00a0points\u00a0(pIs)\u00a0while\u00a0maintaining\u00a0binding\u00a0activities.\n    </p>The\u00a0humanized\u00a0monoclonal\u00a0antibody,\u00a0445-3,\u00a0comprising\u00a0HCDR1\u00a0of\u00a0SEQ\u00a0ID\u00a0NO:\u00a03,\u00a0HCDR2\u00a0of\u00a0SEQ\u00a0ID\u00a0NO:\u00a024,\u00a0HCDR\u00a03\u00a0of\u00a0SEQ\u00a0ID\u00a0NO:\u00a05,\u00a0LCDR1\u00a0of\u00a0SEQ\u00a0ID\u00a0NO:\u00a025,\u00a0LCDR2\u00a0of\u00a0SEQ\u00a0ID\u00a0NO:\u00a019,\u00a0and\u00a0LCDR3\u00a0of\u00a0SEQ\u00a0ID\u00a0NO:\u00a08\u00a0(see\u00a0Table\u00a03)\u00a0,\u00a0was\u00a0constructed\u00a0from\u00a0the\u00a0maturation\u00a0process\u00a0described\u00a0above,\u00a0and\u00a0characterized\u00a0in\u00a0detail.\u00a0Antibody\u00a0445-3\u00a0was\u00a0also\u00a0made\u00a0into\u00a0an\u00a0IgG2\u00a0version\u00a0(445-3\u00a0IgG2)\u00a0comprising\u00a0the\u00a0Fc\u00a0domain\u00a0of\u00a0wild-type\u00a0heavy\u00a0chain\u00a0of\u00a0human\u00a0IgG2,\u00a0and\u00a0an\u00a0IgG4\u00a0version\u00a0comprising\u00a0the\u00a0Fc\u00a0domain\u00a0of\u00a0human\u00a0IgG4\u00a0with\u00a0S228P\u00a0and\u00a0R409K\u00a0mutations\u00a0(445-3\u00a0IgG4)\u00a0.\u00a0The\u00a0results\u00a0showed\u00a0that\u00a0445-3\u00a0and\u00a0445-2\u00a0exhibited\u00a0comparable\u00a0binding\u00a0affinity\u00a0(see\u00a0Table\u00a04\u00a0and\u00a0Table\u00a05)\u00a0.</p>Table\u00a03.\u00a0445\u00a0antibody\u00a0sequences</p></p></p></p>Example\u00a04:\u00a0Binding\u00a0kinetics\u00a0and\u00a0affinity\u00a0determination\u00a0of\u00a0anti-OX40\u00a0antibodies\u00a0by\u00a0SPR</p>The\u00a0anti-OX40\u00a0antibodies\u00a0were\u00a0characterized\u00a0for\u00a0their\u00a0binding\u00a0kinetics\u00a0and\u00a0affinity\u00a0by\u00a0SPR\u00a0assays\u00a0using\u00a0BIAcore\n      <sup>TM</sup>\u00a0T-200\u00a0(GE\u00a0Life\u00a0Sciences)\u00a0.\u00a0Briefly,\u00a0anti-human\u00a0IgG\u00a0antibody\u00a0was\u00a0immobilized\u00a0on\u00a0an\u00a0activated\u00a0CM5\u00a0biosensor\u00a0chip\u00a0(Cat:\u00a0BR100530,\u00a0GE\u00a0Life\u00a0Sciences)\u00a0.\u00a0An\u00a0antibody\u00a0with\u00a0human\u00a0IgG\u00a0Fc\u00a0region\u00a0was\u00a0flowed\u00a0over\u00a0the\u00a0chip\u00a0surface\u00a0and\u00a0captured\u00a0by\u00a0anti-human\u00a0IgG\u00a0antibody.\u00a0Then\u00a0a\u00a0serial\u00a0dilution\u00a0of\u00a0recombinant\u00a0OX40\u00a0protein\u00a0with\u00a0a\u00a0His\u00a0tag\u00a0(Cat:\u00a010481-H08H,\u00a0Sino\u00a0Biological)\u00a0was\u00a0flowed\u00a0over\u00a0the\u00a0chip\u00a0surface\u00a0and\u00a0changes\u00a0in\u00a0surface\u00a0plasmon\u00a0resonance\u00a0signals\u00a0were\u00a0analyzed\u00a0to\u00a0calculate\u00a0the\u00a0association\u00a0rates\u00a0(ka)\u00a0and\u00a0dissociation\u00a0rates\u00a0(kd)\u00a0by\u00a0using\u00a0the\u00a0one-to-one\u00a0Langmuir\u00a0binding\u00a0model\u00a0(BIA\u00a0Evaluation\u00a0Software,\u00a0GE\u00a0Life\u00a0Sciences)\u00a0.\u00a0The\u00a0equilibrium\u00a0dissociation\u00a0constant\u00a0(K\n      <sub>D</sub>)\u00a0was\u00a0calculated\u00a0as\u00a0the\u00a0ratio\u00a0kd/ka.\u00a0The\u00a0results\u00a0of\u00a0SPR-determined\u00a0binding\u00a0profiles\u00a0of\u00a0anti-OX40\u00a0antibodies\u00a0are\u00a0summarized\u00a0in\u00a0Figure\u00a02\u00a0and\u00a0Table\u00a04.\u00a0The\u00a0binding\u00a0profile\u00a0with\u00a0average\u00a0K\n      <sub>D</sub>\u00a0of\u00a0antibody\u00a0445-3\u00a0(9.47\u00a0nM)\u00a0was\u00a0slightly\u00a0better\u00a0than\u00a0antibody\u00a0445-2\u00a0(13.5\u00a0nM)\u00a0and\u00a0445-1\u00a0(17.1\u00a0nM)\u00a0,\u00a0and\u00a0similar\u00a0to\u00a0that\u00a0of\u00a0ch445.\u00a0The\u00a0binding\u00a0profile\u00a0of\u00a0445-3\u00a0IgG4\u00a0was\u00a0similar\u00a0to\u00a0445-3\u00a0(with\u00a0IgG1\u00a0Fc)\u00a0,\u00a0indicating\u00a0that\u00a0the\u00a0change\u00a0in\u00a0Fc\u00a0between\u00a0IgG4\u00a0and\u00a0IgG1\u00a0did\u00a0not\u00a0alter\u00a0the\u00a0specific\u00a0binding\u00a0of\u00a0the\u00a0445-3\u00a0antibody.\n    </p>Table\u00a04.\u00a0Binding\u00a0affinities\u00a0of\u00a0anti-OX40\u00a0antibodies\u00a0by\u00a0SPR</p></p></p>*ch445\u00a0is\u00a0comprised\u00a0of\u00a0Mu445\u00a0variable\u00a0domains\u00a0fused\u00a0to\u00a0human\u00a0IgG1wt/kappa\u00a0constant\u00a0regions\u00a0Example\u00a05:\u00a0Determining\u00a0the\u00a0binding\u00a0affinity\u00a0of\u00a0anti-OX40\u00a0antibodies\u00a0to\u00a0OX40\u00a0expressed\u00a0on\u00a0HuT78\u00a0cells</p>To\u00a0evaluate\u00a0the\u00a0binding\u00a0activity\u00a0of\u00a0anti-OX40\u00a0antibodies\u00a0to\u00a0bind\u00a0OX40\u00a0expressed\u00a0on\u00a0the\u00a0surface\u00a0of\u00a0live\u00a0cells,\u00a0HuT78\u00a0cells\u00a0were\u00a0transfected\u00a0with\u00a0human\u00a0OX40\u00a0as\u00a0described\u00a0in\u00a0Example\u00a01\u00a0to\u00a0create\u00a0an\u00a0OX40\u00a0expressing\u00a0line.\u00a0Live\u00a0HuT78/OX40\u00a0cells\u00a0were\u00a0seeded\u00a0in\u00a096-well\u00a0plate\u00a0and\u00a0were\u00a0incubated\u00a0with\u00a0a\u00a0serial\u00a0dilution\u00a0of\u00a0various\u00a0anti-OX40\u00a0antibodies.\u00a0Goat\u00a0anti-Human\u00a0IgG-FITC\u00a0(Cat:\u00a0A0556,\u00a0Beyotime)\u00a0was\u00a0used\u00a0as\u00a0a\u00a0secondary\u00a0antibody\u00a0to\u00a0detect\u00a0antibody\u00a0binding\u00a0to\u00a0the\u00a0cell\u00a0surface.\u00a0EC\n      <sub>50</sub>\u00a0values\u00a0for\u00a0dose-dependent\u00a0binding\u00a0to\u00a0human\u00a0OX40\u00a0were\u00a0determined\u00a0by\u00a0fitting\u00a0the\u00a0dose-response\u00a0data\u00a0to\u00a0the\u00a0four-parameter\u00a0logistic\u00a0model\u00a0with\u00a0GraphPad\u00a0Prism.\u00a0As\u00a0shown\u00a0in\u00a0Figure\u00a03\u00a0and\u00a0Table\u00a05,\u00a0the\u00a0OX40\u00a0antibodies\u00a0had\u00a0high\u00a0affinity\u00a0to\u00a0OX40.\u00a0It\u00a0was\u00a0al",
    "o\u00a0and\u00a0Fc\u00a0are\u00a0the\u00a0observed\u00a0and\u00a0calculated\u00a0structure\u00a0factor\u00a0amplitudes,\u00a0respectively.\n    </p><sup>c</sup>\u00a0R\n      <sub>free</sub>=\u2211|Fo-Fc|/\u2211|Fo|,\u00a0calculated\u00a0using\u00a0a\u00a0test\u00a0data\u00a0set,\u00a05%of\u00a0total\u00a0data\u00a0randomly\u00a0selected\u00a0from\u00a0the\u00a0observed\u00a0reflections.\n    </p>Example\u00a08:\u00a0Epitope\u00a0identification\u00a0of\u00a0antibody\u00a0445-3\u00a0by\u00a0SPR</p>Guided\u00a0by\u00a0the\u00a0co-crystal\u00a0structure\u00a0of\u00a0OX40\u00a0and\u00a0antibody\u00a0445-3\u00a0Fab,\u00a0we\u00a0selected\u00a0and\u00a0generated\u00a0a\u00a0series\u00a0of\u00a0single\u00a0mutations\u00a0in\u00a0human\u00a0OX40\u00a0protein\u00a0to\u00a0further\u00a0identify\u00a0the\u00a0key\u00a0epitopes\u00a0of\u00a0anti-OX40\u00a0antibodies\u00a0of\u00a0the\u00a0present\u00a0disclosure.\u00a0The\u00a0single\u00a0point\u00a0mutations\u00a0were\u00a0made\u00a0to\u00a0a\u00a0human\u00a0OX40/IgG1\u00a0fusion\u00a0construct\u00a0with\u00a0a\u00a0site-directed\u00a0mutagenesis\u00a0kit\u00a0(Cat:\u00a0AP231-11,\u00a0TransGen)\u00a0.\u00a0The\u00a0desired\u00a0mutations\u00a0were\u00a0verified\u00a0by\u00a0sequencing.\u00a0Expression\u00a0and\u00a0preparation\u00a0of\u00a0the\u00a0OX40\u00a0mutants\u00a0were\u00a0achieved\u00a0by\u00a0transfection\u00a0into\u00a0293G\u00a0cells\u00a0and\u00a0purified\u00a0using\u00a0a\u00a0protein\u00a0A\u00a0column\u00a0(Cat:\u00a017-5438-02,\u00a0GE\u00a0Life\u00a0Sciences)\u00a0.</p>Binding\u00a0affinity\u00a0of\u00a0the\u00a0OX40\u00a0point\u00a0mutants\u00a0to\u00a0a\u00a0445-3\u00a0Fab\u00a0were\u00a0characterized\u00a0by\u00a0SPR\u00a0assays\u00a0using\u00a0BIAcore\u00a08K\u00a0(GE\u00a0Life\u00a0Sciences)\u00a0.\u00a0Briefly,\u00a0OX40\u00a0mutants\u00a0and\u00a0wild\u00a0type\u00a0OX40\u00a0were\u00a0immobilized\u00a0on\u00a0a\u00a0CM5\u00a0biosensor\u00a0chip\u00a0(Cat:\u00a0BR100530,\u00a0GE\u00a0Life\u00a0Sciences)\u00a0using\u00a0EDC\u00a0and\u00a0NHS.\u00a0Then\u00a0a\u00a0serial\u00a0dilution\u00a0of\u00a0445-3\u00a0Fab\u00a0in\u00a0HBS-EP+\u00a0buffer\u00a0(Cat:\u00a0BR-1008-26,\u00a0GE\u00a0Life\u00a0Sciences)\u00a0was\u00a0flowed\u00a0over\u00a0the\u00a0chip\u00a0surface\u00a0using\u00a0a\u00a0contact\u00a0time\u00a0of\u00a0180\u00a0s\u00a0and\u00a0a\u00a0dissociation\u00a0time\u00a0of\u00a0600\u00a0s\u00a0at\u00a030\u00a0\u03bcl/min.\u00a0The\u00a0changes\u00a0in\u00a0surface\u00a0plasmon\u00a0resonance\u00a0signals\u00a0were\u00a0analyzed\u00a0to\u00a0calculate\u00a0the\u00a0association\u00a0rates\u00a0(ka)\u00a0and\u00a0dissociation\u00a0rates\u00a0(kd)\u00a0by\u00a0using\u00a0the\u00a0one-to-one\u00a0Langmuir\u00a0binding\u00a0model\u00a0(BIA\u00a0Evaluation\u00a0Software,\u00a0GE\u00a0Life\u00a0Sciences)\u00a0.\u00a0The\u00a0equilibrium\u00a0dissociation\u00a0constant\u00a0(K\n      <sub>D</sub>)\u00a0was\u00a0calculated\u00a0as\u00a0the\u00a0ratio\u00a0kd/ka.\u00a0The\u00a0K\n      <sub>D</sub>\u00a0shift\u00a0fold\u00a0of\u00a0mutant\u00a0was\u00a0calculated\u00a0as\u00a0the\u00a0ratio\u00a0Mutant\u00a0K\n      <sub>D</sub>/WT\u00a0K\n      <sub>D</sub>.\u00a0The\u00a0profiles\u00a0of\u00a0epitope\u00a0identification\u00a0determined\u00a0by\u00a0SPR\u00a0are\u00a0summarized\u00a0in\u00a0Figure\u00a05\u00a0and\u00a0Table\u00a08.\u00a0The\u00a0results\u00a0indicated\u00a0that\u00a0mutation\u00a0of\u00a0residues\u00a0H153,\u00a0I165\u00a0and\u00a0E167\u00a0to\u00a0alanine\u00a0in\u00a0OX40\u00a0significantly\u00a0reduced\u00a0antibody\u00a0445-3\u00a0binding\u00a0to\u00a0OX40,\u00a0and\u00a0the\u00a0mutation\u00a0of\u00a0residues\u00a0T154\u00a0and\u00a0D170\u00a0to\u00a0alanine\u00a0had\u00a0moderate\u00a0reduction\u00a0of\u00a0antibody\u00a0445-3\u00a0binding\u00a0to\u00a0OX40.\n    </p>The\u00a0detailed\u00a0interactions\u00a0between\u00a0antibody\u00a0445-3\u00a0and\u00a0residues\u00a0H153,\u00a0T154,\u00a0I165,\u00a0E167\u00a0and\u00a0D170\u00a0of\u00a0OX40\u00a0are\u00a0shown\u00a0in\u00a0Figure\u00a06.\u00a0The\u00a0side\u00a0chain\u00a0of\u00a0H153\u00a0on\u00a0OX40\u00a0was\u00a0 surrounded\u00a0by\u00a0a\u00a0small\u00a0pocket\u00a0of\u00a0445-3\u00a0on\u00a0the\u00a0interaction\u00a0interface,\u00a0forming\u00a0hydrogen\u00a0bonds\u00a0with\u00a0 \n      <sub>heavy</sub>S31\u00a0and\u00a0\n      <sub>heavy</sub>G102\u00a0and\u00a0pi-pi\u00a0stacking\u00a0with\u00a0\n      <sub>heavy</sub>Y101.\u00a0The\u00a0side\u00a0chain\u00a0of\u00a0E167\u00a0formed\u00a0hydrogen\u00a0bonds\u00a0with\u00a0\n      <sub>heavy</sub>Y50\u00a0and\u00a0\n      <sub>heavy</sub>N52,\u00a0while\u00a0D170\u00a0formed\u00a0a\u00a0hydrogen\u00a0bond\u00a0and\u00a0a\u00a0salt\u00a0bridge\u00a0with\u00a0\n      <sub>heavy</sub>S31\u00a0and\u00a0\n      <sub>heavy</sub>K28,\u00a0respectively,\u00a0which\u00a0can\u00a0further\u00a0stabilize\u00a0the\u00a0complex.\u00a0Van\u00a0der\u00a0Waals\u00a0(VDW)\u00a0interactions\u00a0between\u00a0T154\u00a0and\u00a0\n      <sub>heavy</sub>Y105,\u00a0I165\u00a0and\u00a0\n      <sub>heavy</sub>R59\u00a0contributed\u00a0to\u00a0a\u00a0high\u00a0affinity\u00a0of\u00a0antibody\u00a0445-3\u00a0to\u00a0OX40.\n    </p>In\u00a0conclusion,\u00a0residues\u00a0H153,\u00a0I165\u00a0and\u00a0E167\u00a0of\u00a0OX40\u00a0were\u00a0identified\u00a0as\u00a0important\u00a0residues\u00a0to\u00a0interact\u00a0with\u00a0antibody\u00a0445-3.\u00a0In\u00a0addition,\u00a0amino\u00a0acids\u00a0T154\u00a0and\u00a0D170\u00a0of\u00a0OX40\u00a0are\u00a0als"
]